Cite

HARVARD Citation

    Sebert, M. et al. (n.d.). Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment. Leukemia research. pp. S54-. [Online]. 
  
Back to record